Pharming today celebrates “hae day :-)” – the global awareness day for hereditary angioedema, a rare life-threatening condition.
Pharming Group reports interim financial results for the first quarter of 2019
RUCONEST® (conestat alfa)
RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE
View our financial calendar and what conferences, meetings and congresses we will visit in 2019 on our upcoming events page.
Our innovative technology and processes are aimed at purification and formulation of recombinant products. We are continuously looking for highly talented and motivated individuals to join our team.